Novartis AG (NVS)
107.38
+0.43
(+0.40%)
USD |
NYSE |
Jun 25, 16:00
107.38
0.00 (0.00%)
After-Hours: 18:57
Novartis Research and Development Expense (Annual): 11.37B for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 11.37B |
| December 31, 2022 | 9.172B |
| December 31, 2021 | 8.641B |
| December 31, 2020 | 8.98B |
| December 31, 2019 | 9.402B |
| December 31, 2018 | 8.489B |
| December 31, 2017 | 8.389B |
| December 31, 2016 | 9.039B |
| December 31, 2015 | 8.935B |
| December 31, 2014 | 9.086B |
| December 31, 2013 | 9.071B |
| December 31, 2012 | 8.588B |
| December 31, 2011 | 9.583B |
| Date | Value |
|---|---|
| December 31, 2010 | 9.07B |
| December 31, 2009 | 7.469B |
| December 31, 2008 | 7.217B |
| December 31, 2007 | 6.43B |
| December 31, 2006 | 5.321B |
| December 31, 2005 | 4.797B |
| December 31, 2004 | 4.152B |
| December 31, 2003 | 3.729B |
| December 31, 2002 | 2.843B |
| December 31, 2001 | 2.528B |
| December 31, 2000 | 2.885B |
| December 31, 1999 | 2.666B |
| December 31, 1998 | 2.839B |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
8.641B
Minimum
2021
11.37B
Maximum
2023
9.513B
Average
9.172B
Median
2022
Research and Development Expense (Annual) Benchmarks
| Roche Holding AG | 15.81B |
| AstraZeneca PLC | 10.94B |
| Novo Nordisk A/S | 4.710B |
| Bristol-Myers Squibb Co | 9.299B |
| MorphoSys AG | 307.04M |